Secondary analysis of 65 Black patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE trial: darolutamide plus ADT reduced risk of radiological progression or death by 49% vs placebo plus ADT, consistent with the overall trial.
Secondary analysisn = 65
Trinh et al. Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial